Assessment of ibrutinib plus rituximab in front-line CLL (FLAIR trial): study protocol for a phase III randomised controlled trial

BACKGROUND: Treatment of chronic lymphocytic leukaemia (CLL) has seen a substantial improvement over the last few years. Combination immunochemotherapy, such as fludarabine, cyclophosphamide and rituximab (FCR), is now standard first-line therapy. However, the majority of patients relapse and requir...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Trials
Main Authors: Collett, Laura, Howard, Dena R., Munir, Talha, McParland, Lucy, Oughton, Jamie B., Rawstron, Andy C., Hockaday, Anna, Dimbleby, Claire, Phillips, David, McMahon, Kathryn, Hulme, Claire, Allsup, David, Bloor, Adrian, Hillmen, Peter
פורמט: Artigo
שפה:Inglês
יצא לאור: BioMed Central 2017
נושאים:
Study Protocol
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC5568356/
https://ncbi.nlm.nih.gov/pubmed/28830517
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13063-017-2138-6
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים